HER2 as a novel therapeutic target for cervical cancer

Area of Science:

• Oncology
• Translational Research
• Cancer Genomics

Background:

• Standard treatments for cervical cancer, surgery and radiation, lack efficacy for metastatic or recurrent disease.
• There is a critical need for novel therapeutic targets and effective treatments for advanced cervical cancer.
• Preclinical models are essential for evaluating new therapeutic strategies and drug targets.

Purpose of the Study:

• To establish patient-derived xenograft (PDX) models of cervical cancer for preclinical drug screening.
• To identify molecular alterations and potential therapeutic targets in cervical cancer using PDX models.
• To evaluate the efficacy of targeted therapy in a HER2-amplified cervical cancer model.

Main Methods:

• Generation of 14 patient-derived xenograft (PDX) models of cervical cancer via subrenal implantation.
• Serial passaging of PDX tumors to maintain histopathological and genomic fidelity.
• Molecular profiling including array comparative genomic hybridization and next-generation sequencing.
• Confirmation of HER2 overexpression in patient samples and PDX models.
• In vivo efficacy study of co-administered trastuzumab and lapatinib in HER2-overexpressed PDX models.

Main Results:

• Established histopathologically and genomically homologous PDX models of cervical cancer.
• Identified one HER2-amplified cervical cancer case among 9 molecularly profiled samples.
• Confirmed HER2 overexpression in both the original tumor and its corresponding PDX model.
• Demonstrated significant tumor growth inhibition with combined trastuzumab and lapatinib therapy in HER2-overexpressed PDX models.

Conclusions:

• Patient-derived xenograft models accurately recapitulate cervical cancer's histopathology and genomics.
• HER2 amplification is a targetable alteration in a subset of cervical cancers.
• HER2 inhibitor-based therapy shows potential as a treatment for HER2-amplified cervical cancer refractory to conventional therapies.